An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

The primary objective of this study is to evaluate the effect of immunosuppressive therapy (IST) in participants treated with asfotase alfa who demonstrate immune-mediated loss of effectiveness (LoE).

Start Date29 Jul 2026

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

NCT07113158

/ Not yet recruitingPhase 3IIT

Effect of Aspirin and Folic Acid for Sudden Sensorineural Hearing Loss

The annual incidence of sudden sensorineural hearing loss (SSNHL) is 5 to 20 per 100 000 persons. The pathophysiology of SSNHL and acute vestibulo-cochlear syndromes (VCS) is unknown in more than 70% of cases.
Hypothesis : an inner ear microvascular disease represents the key element in the pathogenesis of SSNHL and acute VCS.
Plasma serotonin has among other tissular effect a vasospastic on microcirculation such as the inner ear microvascularisation. Increased plasma homocysteine has a deleterious effect on vascular endothelium. Inner ear microvascularisation sensitized by an increased homocysteine level and the vascular wall would vasoconstrict under serotonin stimulation inducing ischemia of the vestibular and/or cochlear organs.

Start Date01 Apr 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT07377071

/ Not yet recruitingEarly Phase 1IIT

Impact of Folate Administration on One-Year Mortality in Patients With Infection-Associated Acute Kidney Injury: An Open-Label Randomised Controlled Study

The goal of this clinical trial is to evaluate if taking folic acid (a form of vitamin B9) can help reduce the risk of death and improve kidney recovery in adults with acute kidney injury (AKI) caused by infections or sepsis.
The main question it aims to answer is: Does taking folic acid lower the chance of dying within one year for these patients? This study will also look at other important questions, such as whether folic acid helps kidneys recover faster (within 7 days), prevents long-term kidney problems (progression to chronic kidney disease at 3 months), reduces heart-related events, and is safe.
Researchers will compare the group receiving folic acid (5 mg taken by mouth once daily for 90 days, plus usual care) to the group receiving only usual care (standard treatments like fluids, blood pressure control, antibiotics, and stopping harmful medicines) to see if folic acid provides extra benefits.
Participants will:
1. Be randomly assigned to one of the two groups
2. Receive usual hospital care for their infection and AKI
3. Take the folic acid (or not, depending on their group) every day for 3 months
4. Have blood tests at the start and at 3 months (including to check serum folate levels)
5. Be followed up for 1 year through clinic visits, phone calls, or medical records to track health outcomes like survival, kidney function, and any side effects
This open-label study (both patients and doctors know which treatment is given) will include about 382 adults at Queen Mary Hospital in Hong Kong. It builds on earlier retrospective study data suggesting folic acid might improve survival in similar patients.

Start Date01 Apr 2026

Sponsor / Collaborator

The University of Hong Kong

100 Clinical Results associated with Folic Acid

100 Translational Medicine associated with Folic Acid

100 Patents (Medical) associated with Folic Acid

49,222

Literatures (Medical) associated with Folic Acid

31 Dec 2026·ANNALS OF MEDICINE

Machine learning-based risk factors for acute-on-chronic liver failure in alcohol-associated liver disease

Article

Author: Liangpunsakul, Suthat ; Hu, Linhui ; Cheng, Hao ; Wang, Yan ; Pan, Jing

BACKGROUND:

In patients with alcohol-associated liver disease (ALD), heavy and prolonged alcohol consumption can trigger acute-on-chronic liver failure (ACLF), a condition associated with high early mortality and significant clinical challenges. Early identification of patients at risk is critical for improving outcomes.

AIMS:

We conducted a retrospective observational study of patients diagnosed with ALD between January 2000 and December 2024 to develop a predictive model for ACLF.

METHODS:

Key clinical indicators were selected using LASSO-regularized logistic regression (LR). The final LR model was visualized as a nomogram and compared with four additional machine learning algorithms. Model performance was evaluated using ten-fold cross-validation and area under the curve (AUC), while feature importance was assessed with Shapley Additive exPlanations values.

RESULTS:

Among 210 patients with ALD, LASSO identified four independent predictors of ACLF: total bilirubin (TBIL), folate, vitamin B12 (VitB12) and the difference from the normal value of prothrombin time (ΔPT). The LR model achieved an AUC of 0.970, indicating excellent predictive accuracy.

CONCLUSION:

We developed a robust clinical prediction model combining LR and machine learning approaches. TBIL, folate, VitB12 and ΔPT are key prognostic markers that may enable early risk stratification and timely intervention, potentially reducing ACLF incidence in ALD patients.

31 Dec 2026·DRUG DELIVERY

Folate-targeted gold nanoparticles for doxorubicin delivery in tumor spheroids

Article

Author: Daniele, Raffaella ; Caliceti, Paolo ; Salmaso, Stefano ; Fragassi, Agnese ; Marzaro, Giovanni ; Pesce, Cristiano ; Tognetti, Francesco ; Verona, Marco

Targeted drug delivery systems represent a promising strategy for enhancing the efficacy and specificity of cancer therapy. In this study, 35 nm folate-targeted gold nanoparticles are presented as nanoparticle-drug conjugates obtained by anchoring on their surface lipoyl terminating doxorubicin prodrug (proDoxo) releasable at the endolysosomal acidic pH to prevent off-site toxic effects. Colloidal stable nanoparticles with a density of proDoxo up to 1000 molecules/particle and 2 kDa mPEG-SH coating were obtained. At pH 5, Doxo was completely released from the nanoparticles in 5 days while only 13% was released over the same period at pH 7.4. The nanoparticle decoration with folic acid as a targeting agent bestowed nanosystems with selective drug delivery to folate receptor (FR)-overexpressing cancer cells and controlled intracellular release. This led to enhanced cancer cell killing by folated nanoparticles compared to their nontargeted counterparts. Moreover, folated nanoparticles were found to distribute more homogeneously inside KB^FR+ cancer cell spheroids than non-targeted nanoparticles, resulting in higher spheroid volume reduction.

01 Dec 2026·JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

In vitro and in silico studies of anticancer activities of pectic acid and pectin oligosaccharide in Epstein-Barr virus-positive nasopharyngeal carcinoma

Article

Author: Mohan, Darshini ; Murugaiyah, Vikneswaran ; Teh, Aik-Hong ; Yap, Beow Keat ; Khor, Boon-Keat

Pectic acid (polygalacturonic acid, PGA) and pectin oligosaccharides (POS) have shown selective anticancer activities with cytotoxicity against various cancer cells, including breast adenocarcinoma MCF-7. While promising, their anticancer activities against the nasopharyngeal carcinoma (NPC) have yet to be determined. To this end, the antiproliferation activities of pectic acid and enzymatically derived unsaturated POS trimer were investigated against the EBV-positive NPC cell line, C666-1, as well as on MCF-7 (as positive control) and NIH-3T3 cells (as non-tumorigenic cell model). Our study shows that both POS trimer and PGA can inhibit C666-1 cells' proliferation at concentrations above 20 mg/mL and 2.5 mg/mL, respectively. Previous studies had also demonstrated that one of the key biological targets for these compounds is the human galectin-3 (hGal3). However, the binding mode of pectic acid and the unsaturated POS trimer to human galectin-3 is still lacking. To investigate this, in silico molecular docking and all-atom molecular dynamics simulations were performed. Analysis of the MD trajectories revealed that the unsaturated POS trimer prefers binding to hGal3 oligomer over hGal3 monomer with a ligand: protein monomer ratio of 1:2 and 1:3. On the other hand, both hGal3 monomer and dimer were found to bind stably to the POS 15-mer (as PGA model) along its linear chain throughout the simulation. In conclusion, both unsaturated POS trimer and PGA have the potential to be novel anticancer agents against EBV-positive NPC, though further development to increase their potency and/or selectivity would be necessary.

111

News (Medical) associated with Folic Acid

17 Mar 2026

·www.biospace.com

What the Leucovorin Approval Signals—or Doesn’t—About the FDA’s Rare Disease Stance

FDA Commissioner Marty Makary speaks at a White House press conference on September 22, 2025. / Joyce N. Boghosian, White House Although FDA Commissioner Marty Makary promised “an exciting treatment” for autism, what the agency delivered was a label expansion for leucovorin to treat the ultrarare cerebral folate deficiency. The regulatory process, which relied on a literature review rather than new evidence, stands in contrast to recent rare disease rejections in which the FDA cited a need for more rigorous evidence. FDA observers have noted a disconnect between what agency officials say about the need for regulatory flexibility when considering therapeutics for rare diseases, and a string of rejections of just such candidates. UniQure, for example, has weathered not only a complete response letter (CRL) but also public criticism from FDA officials for attempting to win approval based on an externally controlled pivotal trial. RENENXBIO, Biohaven and Capricor Therapeutics have also received CRLs over the past year. Sen. Ron Johnson (R-WI) has launched an investigation into such rejections. In sharp contrast to these stories, the FDA last week touted its expansion of leucovorin—long approved to ameliorate the effects of certain cancer therapies—to treat cerebral folate deficiency (CFD) linked to a particular genetic variant, an action it said “reflects the agency’s commitment to accelerating cures and expanding treatment options including for patients with serious and unmet needs.” Notably, the expansion was initiated not by a drug company but by the FDA itself after Commissioner Marty Makary promoted leucovorin as a treatment for autism. Agency staffers mined the literature for evidence of leucovorin’s effectiveness in CFD. Unsurprisingly for a disease that has been diagnosed in fewer than 50 people worldwide, that evidence does not include a randomized, controlled trial. The apparent discrepancy in evidence standards “can’t be rationalized in a coherent sense, other than that leucovorin is a drug that is being shaped to fit RFK’s agenda around autism and it’s outside the reach of Vinay Prasad and [the Center for Biologics Evaluation and Research],” Holly Fernandez Lynch, a bioethics and law professor at the University of Pennsylvania, wrote in an email to BioSpace . “This is exactly the sort of thing that makes the public not trust FDA’s decisions, as this is not based in science, it’s based in politics.” The decision “is highly unusual—maybe unprecedented—and I think it’s good and bad,” said Paul Kim, principal at Kendall Square Policy Strategies and a former FDA counsel to the late Senator Edward Kennedy and Congressman Henry Waxman. While the regulatory approach of mining real-world evidence could benefit other rare diseases, Kim agreed there is a political story behind the expansion. A Tenuous Autism Link On Sept. 22, 2025, as part of a White House press conference in which President Donald Trump and members of his administration alleged a link between autism and Tylenol exposure in utero, FDA chief Marty Makary took the podium to deliver what he called good news. “Today, the FDA is filing a federal register notice to change the label on an exciting treatment called prescription leucovorin so that it can be available to children with autism,” he said. “We have a duty to let doctors and the public know. . . . Hundreds of thousands of kids, in my opinion, will benefit.” This came after then–Center for Drug Evaluation and Research Director George Tidmarsh had asked FDA staff in August to look into finding a way to approve leucovorin for autism, STAT News later reported. The drug, a form of folic acid, was originally sponsored by GSK and used to ameliorate the effects of cancer drugs such as methotrexate and fluorouracil. It’s been used off-label to treat CFD since 2009, an expert on the condition told CNN . GSK no longer makes the drug, but some generic suppliers do. CFD has some overlap in symptoms with autism, and a few small studies have explored leucovorin’s use in the more common condition. But according to the American Academy of Pediatrics , “Current evidence is insufficient to support prescribing leucovorin for autism in the absence of CFD.” Tidmarsh and FDA staffers ultimately compromised with a plan to submit leucovorin for approval in CFD rather than autism, STAT reported. GSK reviewed the case reports provided by the FDA and submitted the supplemental New Drug Application to update the indication, a company spokesperson told BioSpace in an email, though it does not plan to resume making or marketing the brand-name version of the drug. At the September press conference, Makary blurred the distinction between CFD and autism and discussed a possible mechanistic link between folate and autism. Policy and regulatory consultant Steven Grossman speculated that leucovorin’s approval for CFD may make the drug materially easier to access for autism as well. “[If] you’re a pediatrician and you’re under pressure from parents—and I’m sure they are—to prescribe leucovorin [for autism] because of the noises coming out of HHS,” the drug’s recent label expansion may make it easier to justify, he suggested. It would still be an off-label prescription but it would be for a drug that’s approved for a pediatric disease and not just for cancer. “While there may be more going on,” Grossman said, “the whole deal looks very much like a gigantic ‘wink-wink’ from the administration.” A Glimpse of What Could Be As Kim sees it, with the press conference and what followed, “we get this highly unsatisfactory, patient-adverse lifting of expectations and crashing of them with the announcement on CFD.” Yet for him, the episode points to what’s possible, namely that “many, many very rare diseases . . . could benefit from this approach” of mining real-world evidence. With more research funding and needed infrastructure in place, “I would be not surprised to see multiple approvals of very rare disorder therapies like leucovorin, either repurposed or novel ones, and a real renaissance,” Kim said—one that is not dependent on the financial markets or emerging company formation but rather taps into the ongoing work of academics and clinicians. As it stands, he said, the leucovorin label expansion is “like hanging a Christmas ornament high on the tree, but there’s nothing else on the tree.”

Drug Approval

11 Mar 2026

·www.drugs.com

FDA Approves Drug for Rare Brain Disorder, Not Autism

WEDNESDAY, March 11, 2026 — The U.S. Food and Drug Administration (FDA) has approved a generic drug for a very rare brain disorder, but said it should not be considered a treatment for autism . On Tuesday, the agency cleared leucovorin for people with a genetic condition that prevents enough folate, a form of vitamin B, from reaching the brain. The FDA estimates the disorder affects fewer than 1 in a million people in the United States. The decision follows months of ambiguity after officials said the drug might help people with autism. In September, President Donald Trump and FDA Commissioner Dr. Marty Makary said the medication was being reviewed as a possible treatment for autism. “It might be 20, 40, 50% of kids with autism,” Makary said at the time. But FDA officials said Monday that the agency later focused only on the strongest scientific evidence. That evidence only supported the drug’s use for people with the rare genetic mutation affecting folate in the brain. Officials also noted that one study supporting the drug’s use for autism was retracted earlier this year. Autism researchers say the drug has not been proven to help most people with the condition. “There is no evidence to say that leucovorin will help most people with autism, and there’s certainly no evidence to say it’s safe,” Dr. Alycia Halladay of the Autism Science Foundation, told The Associated Press in an interview. Leucovorin is a lab-made form of folate that doctors have used for years to reduce side effects from certain chemotherapy medications and to treat a rare blood disorder. People with the condition targeted by Tuesday’s approval may develop movement problems, seizures and other neurological symptoms that can sometimes resemble autism. But major medical groups are cautious about using leucovorin for autism. The American Academy of Pediatrics does not recommend its use for children with autism, including those with a condition called cerebral folate deficiency. But despite the uncertainty, prescriptions for leucovorin have increased. A recent study in The Lancet found that prescriptions for children ages 5 to 17 rose 71% in the three months following the White House announcement last September. “We’ve seen huge increases in leucovorin prescriptions for autism because of the initial premature and ill-informed announcement that it can treat autism symptoms,” David Mandell , an autism expert at the University of Pennsylvania, told The AP . "Now families are experiencing whiplash about what constitutes best practice for their children," Mandell added. Some families have also reported difficulty filling prescriptions recently due to supply shortages. FDA officials said the agency is allowing foreign manufacturers to help with supply. The drug’s original maker, GSK, does not plan to relaunch its version. Halladay warned that parents should be careful about trying the drug for autism. Reports have linked the medication to side effects such as irritability, aggression and hyperactivity in some patients. “If parents are insistent on trying this they should know that it may cause harm and it may do no good,” Halladay said. Researchers say autism likely results from a mix of genetic and environmental factors, and there is still no single known cause. Sources The Associated Press, March 10, 2026

Drug Approval

11 Mar 2026

·www.drugs.com

FDA Approves Leucovorin for Rare Brain Disorder, Not Autism

WEDNESDAY, March 11, 2026 — The U.S. Food and Drug Administration (FDA) has approved a generic drug for a very rare brain disorder, but said it should not be considered a treatment for autism . On Tuesday, the agency cleared leucovorin for people with a genetic condition that prevents enough folate, a form of vitamin B, from reaching the brain. The FDA estimates the disorder affects fewer than 1 in a million people in the United States. The decision follows months of ambiguity after officials said the drug might help people with autism. In September, President Donald Trump and FDA Commissioner Dr. Marty Makary said the medication was being reviewed as a possible treatment for autism. “It might be 20, 40, 50% of kids with autism,” Makary said at the time. But FDA officials said Monday that the agency later focused only on the strongest scientific evidence. That evidence only supported the drug’s use for people with the rare genetic mutation affecting folate in the brain. Officials also noted that one study supporting the drug’s use for autism was retracted earlier this year. Autism researchers say the drug has not been proven to help most people with the condition. “There is no evidence to say that leucovorin will help most people with autism, and there’s certainly no evidence to say it’s safe,” Dr. Alycia Halladay of the Autism Science Foundation, told The Associated Press in an interview. Leucovorin is a lab-made form of folate that doctors have used for years to reduce side effects from certain chemotherapy medications and to treat a rare blood disorder. People with the condition targeted by Tuesday’s approval may develop movement problems, seizures and other neurological symptoms that can sometimes resemble autism. But major medical groups are cautious about using leucovorin for autism. The American Academy of Pediatrics does not recommend its use for children with autism, including those with a condition called cerebral folate deficiency . But despite the uncertainty, prescriptions for leucovorin have increased. A recent study in The Lancet found that prescriptions for children ages 5 to 17 rose 71% in the three months following the White House announcement last September. “We’ve seen huge increases in leucovorin prescriptions for autism because of the initial premature and ill-informed announcement that it can treat autism symptoms,” David Mandell , an autism expert at the University of Pennsylvania, told The AP . "Now families are experiencing whiplash about what constitutes best practice for their children," Mandell added. Some families have also reported difficulty filling prescriptions recently due to supply shortages. FDA officials said the agency is allowing foreign manufacturers to help with supply. The drug’s original maker, GSK, does not plan to relaunch its version. Halladay warned that parents should be careful about trying the drug for autism. Reports have linked the medication to side effects such as irritability, aggression and hyperactivity in some patients. “If parents are insistent on trying this they should know that it may cause harm and it may do no good,” Halladay said. Researchers say autism likely results from a mix of genetic and environmental factors, and there is still no single known cause. Sources The Associated Press, March 10, 2026

Drug Approval

100 Deals associated with Folic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
D00070	Folic Acid	V04CX02 B03BB01	DB00158

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Megaloblastic	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Folic Acid Deficiency	Japan	Fuji Pharma Co., Ltd.	01 Aug 1950
Neural Tube Defects	United States	Eli Lilly & Co.	02 Jun 1947

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperhomocysteinemia	Phase 2	China	Beijing Silian Pharmaceutical Co., Ltd.	28 Aug 2025
Non-squamous non-small cell lung cancer	Phase 2	Australia	Eli Lilly & Co.	01 Feb 2008
Non-squamous non-small cell lung cancer	Phase 2	Italy	Eli Lilly & Co.	01 Feb 2008
Non-squamous non-small cell lung cancer	Phase 2	Mexico	Eli Lilly & Co.	01 Feb 2008
Non-squamous non-small cell lung cancer	Phase 2	Spain	Eli Lilly & Co.	01 Feb 2008
Rectal Cancer	Phase 2	Sweden	Eli Lilly Group Ltd.	04 May 2006
Contraception	Phase 1	-	Johnson & Johnson Pharmaceutical Research & Development LLC	01 Jan 2005
Diabetic peripheral neuropathy	Clinical	-	OPKO Health, Inc.	-
Ischemic stroke	IND Approval	China	Beijing Silian Pharmaceutical Co., Ltd.	24 Sep 2024
Homocysteinemia	IND Approval	China	Beijing Silian Pharmaceutical Co., Ltd.	09 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00130065 \| NCT00120822 (Pubmed \| Cochrane Database Syst Rev)	Not Applicable	Malaria	3,486	Folic acid (alone or in combination with other vitamins and minerals) + antifolate antimalarials	ienqlisraf(qsuwlxtoya): RR = 1.97 (95.0% CI, 1.44 - 2.7), P-Value = 1.97 View more	Negative	18 Feb 2026
				Placebo/no folic acid + antifolate antimalarial medications
NCT04024254 (CTgov)	Phase 4	Ovarian Cancer \| Breast Cancer \| Folic Acid Deficiency	10	Folic Acid Tablet	sjrusxnsqj(qolbkxxczx) = vhvgxybfwz rwvririhte (rantfvtvyk, huwqufoiwq - mulhzexlja)	-	21 Nov 2025
NCT04354428 (CTgov)	Phase 2/3	COVID-19	289	Ascorbic Acid+Folic Acid (Ascorbic Acid and Folic Acid)	oivmunjhwc = tjppjmlzlt evqmmdpwkl (liolcpcfnn, xvdkbjvrwj - hxfezowfqf) View more	-	08 Aug 2022
				Hydroxychloroquine Sulfate+Folic Acid (Hydroxychloroquine and Folic Acid)	oivmunjhwc = quvlagsmko evqmmdpwkl (liolcpcfnn, pnroqhxzwe - kkmrhjjgkf) View more
NCT03994731 (MIRROR RCT \| MIRROR, CTgov)	Phase 4	Gout	152	gout flare prophylaxis regimen+acetaminophen+methylprednisolone+fexofenadine+folic acid+methotrexate+Pegloticase (Pegloticase + MTX)	muavgbbzty = ynviwhaowb bsishxkaiw (tolhvdzcsp, hlxymrxbha - umcplfgwii) View more	-	16 May 2022
				placebo+acetaminophen+methylprednisolone+fexofenadine+folic acid+methotrexate+Pegloticase (Pegloticase + Placebo)	muavgbbzty = oqziihychx bsishxkaiw (tolhvdzcsp, pitomluxqx - uiunncxqgf) View more
NCT00950989 (CTgov)	Phase 2	Rheumatoid Arthritis	252	Placebo+folic acid+Methotrexate (Placebo)	poncxqpdtx = cbjdukcijx pfoxbjmbiu (iddcmljbfd, chqhzmyjps - dnsptwlait) View more	-	21 Dec 2021
				Brodalumab+folic acid+Methotrexate (Brodalumab 70 mg)	poncxqpdtx = snraorcnbb pfoxbjmbiu (iddcmljbfd, gutxycpyne - kgfmrvgxol) View more
NCT02930343 (CTgov)	Phase 3	Rheumatoid Arthritis	136	Hydroxychloroquine+Prednisolone+Folic Acid+Methotrexate+Leflunomide (Group 1- MTX+LEF+HCQ)	rdtxffybye = saeuyloouf uwuphqbhjj (xrectalqwy, zlkwwypyzk - bknkbcwnyg) View more	-	10 Jun 2021
				Hydroxychloroquine+Prednisolone+Folic Acid+Methotrexate+Sulfasalazine (Group 2- MTX+SSZ+HCQ)	rdtxffybye = nvxncggzec uwuphqbhjj (xrectalqwy, lnisodpjlr - mkompbzumj) View more
NCT03172325 (CTgov)	Phase 3	Rheumatoid Arthritis	136	Adalimumab+Prednisolone+Folic Acid+Methotrexate (CinnaGen Adalimumab)	iqhbxiofri = cfbithnzcu epqhsepxpb (fltmcenfaf, tvwijjvwpw - cznnrbwgwr) View more	-	02 Feb 2021
				Adalimumab+Prednisolone+Folic Acid+Methotrexate (AbbVie Adalimumab)	iqhbxiofri = nhysxvigmt epqhsepxpb (fltmcenfaf, qbavdtgiph - avojtrvqbg) View more
NCT03635957 (MIRROR OL \| MIRROR-OL \| MIRROR, CTgov)	Phase 4	Gout \| Hyperuricemia	14	Infusion Reaction (IR) Prophylaxis+Folic Acid+Methotrexate (MTX)+Pegloticase	fvtdfuvmoo = vcdgfvcnln bvlhxrwfzd (zpmlvdvhib, jvxdzspftf - byqdcigaqk) View more	-	18 Nov 2020
NCT00655980 (VINO, CTgov)	Not Applicable	Coronary Artery Disease	687	placebo+nitrous oxide (Comparator)	hipcejucit = fthcsyptpu wekxcievuk (sfonwzqniz, zejwsapkuh - zpikcrqths) View more	-	01 Oct 2020
				standard of care (Standard of Care)	hipcejucit = uyaahanvhx wekxcievuk (sfonwzqniz, zohvpomtjs - uowzoqcowv) View more
NCT01355159 (FACT, CTgov)	Phase 3	Pre-Eclampsia	2,464	Folic Acid 4 mg (Folic Acid 4 mg)	epudbgqvpy = gtuvsjboxi livsrvleth (paituoqxup, gxrokjaiwf - qzhgqlfham) View more	-	07 Jul 2020
				Placebo (Placebo)	epudbgqvpy = snoilddmpm livsrvleth (paituoqxup, bybfrgpwke - vyhfbgmmnl) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis